Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548918 | 0.84 | PPARG (0.59) | CYP1A2PPARGPPARAMAPK1SCN4A | |
| SCHEMBL18990419 | 0.82 | KDM4E (0.47) | CYP1A2MAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18990422 | 0.82 | KDM4E (0.47) | CYP1A2MAPK1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4599078 | 0.81 | CYP1A2 (0.58) | CYP1A2PPARGPPARAMAPK1SCN4A | |
| SCHEMBL5354587 | 0.79 | CYP1A2 (0.74) | CYP1A2PPARGPPARAMAPK1SCN4A | |
| Carbamic Acid SCHEMBL34493 | 0.78 | CYP1A2 (0.68) | CYP1A2PPARGPPARAMAPK1SCN4A | |
| Chlorphenesin Carbamate SCHEMBL2939463 | 0.78 | CYP1A2 (1.00) | CYP1A2PPARGPPARAMAPK1SMN1; SMN2 | |
| Chlorphenesin Carbamate SCHEMBL34492 | 0.78 | CYP1A2 (1.00) | CYP1A2PPARGPPARAMAPK1SMN1; SMN2 | |
| SCHEMBL24272288 | 0.77 | CYP1A2 (0.56) | CYP1A2PPARGPPARAMAPK1SCN4A | |
| SCHEMBL11265589 | 0.76 | CYP1A2 (0.49) | CYP1A2PPARGPPARAMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | CYP1A2 1209/4885PPARG 527/4885PPARA 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.